Cancer cure for 32 cancer types: Results from the EUROCARE-5 study

Luigino Dal Maso[1§], Chiara Panato[1], Andrea Tavilla[2], Stefano Guzzinati[3], Diego Serraino[1], Sandra Mallone[2], Laura Botta[4], Olayide Boussari[5], Riccardo Capocaccia[6], Marc Colonna[7], Emanuele Crocetti[8], Agnes Dumas[9], Tadek Dyba[10], Silvia Franceschi[1], Gemma Gatta[4], Anna Gigli[11], Francesco Giusti[10], Valerie Jooste[5], Pamela Minicozzi[12,13], Luciana Neamtiu[10], Gaëlle Romain[5], Manuel Zorzi[3], Roberta De Angelis[14], Silvia Francisci[2§], and the EUROCARE-5 Working Group[15]

[1]Cancer Epidemiology Unit, Centro di Riferimento Oncologico (CRO), IRCCS, Aviano, Italy; [2]National Center for Prevention and Health Promotion, Italian National Institute of Health (ISS), Rome, Italy; [3]Veneto Tumour Registry, Azienda Zero, Padua, Italy; [4]Evaluative Epidemiology Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; [5]Registre Bourguignon des Cancers Digestifs, Dijon, France; [6]Editorial board, Epidemiologia & Prevenzione, Milan, Italy; [7]Registre du Cancer de l'Isère, Grenoble, France; [8]Romagna Cancer Registry, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola, Italy-Azienda Usl della Romagna, Forlì, Italy; [9]National Institute for Health and Medical Research (INSERM), Paris, France; [10]European Commission, Joint Research Centre (JRC), Ispra, Italy; [11]Institute for Research on Population and Social Policies, National Research Council, Rome, Italy; [12]Analytical Epidemiology and Health Impact Unit, Research Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy; [13]Cancer Survival Group, Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, UK; [14]Department of Oncology and Molecular Medicine, Italian National Institute of Health (ISS), Rome, Italy; **EUROCARE-5 Working Group: Austria**: M. Hackl, P. Ihle (*Austrian CR*); **Denmark**: H. Storm, G. Engholm (*Danish Cancer Society*); **Estonia**: M. Mägi (*Estonian CR*); K. Innos* (*National Institute for Health Development*); **Finland**: N. Malila, K. Seppä (*Finnish CR*); **France**: M. Velten (*Bas Rhin CR*); V. Jooste* (*Bourguignon Digestive CR*); V. Bouvier, G. Launoy (*Calvados Digestive Tract Registry*); A. V. Guizard (*Calvados, General CR*); A. S. Woronoff (*Doubs CR*); A. Monnereau* (*Gironde Haematological Malignancies CR*); N. Bossard* (*Hospices Civils de Lyon*); Z. Uhry (*Hospices Civils*

de Lyon; Institut de Veille Sanitaire); M. Colonna (*Isère CR*); B. Lapôtre-Ledoux (*Somme CR*); P. Grosclaude (*Tarn CR*); **Germany**: H. Brenner (*German Cancer Research Center*); B. Holleczek (*Saarland CR*); A. Katalinic* (*Schleswig-Holstein CR*); **Iceland**: H. Birgisson, L. Tryggvadóttir (*Icelandic CR*); **Italy**: C. Buzzoni (*Associazione Italiana Registri Tumori*); S. Ferretti (*Ferrara CR*); A. Barchielli, G. Manneschi (*Firenze-Prato CR*); G. Gatta*, M. Sant*, C. Amati, P. Baili*, S. Bonfarnuzzo, L. Botta, E. Meneghini, A. Trama (*Fondazione IRCCS Istituto Nazionale dei Tumori, Milan*); R. De Angelis*, M. Caldora, C. Di Benedetto, S. Francisci, F. Galati, S. Mallone, D. Pierannunzio, M. Tallon, S. Rossi*, M. Santaquilani, A. Tavilla (*Istituto Superiore di Sanità, Rome*); R. A. Filiberti, E. Marani (*Liguria CR, Ospedale Policlinico San Martino IRCCS*); G. Spagnoli, C. Cirilli (*Modena CR*); M. Michiara (*Parma CR*); R. Zanetti, S. Rosso (*Piemonte CR*); R. Tumino (*Ragusa CR*); F. Falcini (*Romagna CR, IRCCS AUSL-IRST Meldola*); G. Tagliabue, P. Contiero (*Varese Province CR, Fondazione IRCCS Istituto Nazionale dei Tumori*); M. Rugge, S. Guzzinati (*Veneto CR*); F. Berrino*, R. Capocaccia*; **Norway**: T. B. Johannesen* (*Norwegian CR*); **Poland**: J. Rachtan (*Cracow CR*); S. Góźdź, P. Macek (*Kielce CR*); M. Bielska-Lasota* (*National Institute of Public Health-NIH, Warszawa*); M. Motnyk (*Silesia CR, Gliwice*); **Slovakia**: C. Safaei Diba (*Slovakian National CR*); **Slovenia**: V. Zadnik, T. Zagar (*Cancer Registry of Republic of Slovenia*); **Spain**: A. Lopez de Munain, L. Gil (*Basque Country, Euskadi-CIBERESP CR*); R. Marcos-Gragera* (*Girona CR, CIBERESP, ICO, IDIBGI*); E. Ardanaz, M. Guevara (*Navarra-CIBERESP CR*); J. Galceran, M. Carulla (*Tarragona CR*); **Sweden**: S. Khan (*Swedish CR*); **Switzerland**: K. Staehelin (*Basel CR*); S. M. Mousavi, E. Walser-Domjan (*East Switzerland CR*); C. Bouchardy, E. Rapiti (*Geneva CR*); S. M. Mousavi, C. Herrmann (*Grisons-Glarus CR*); M. Lorez (*NICER*); I. Konzelmann (*Valais CR*); **The Netherlands**: O. Visser*, K. Aben (*The Netherlands CR*); **UK-England**: M. Coleman, C. Allemani, B. Rachet (*London School of Hygiene and Tropical Medicine*); J. Rashbass, J. Broggio (*Public Health England*); **UK-Northern Ireland**: A. Gavin* (*Northern Ireland CR*); **UK-Scotland**: D. Morrison, R. Black (*Scottish CR*); **UK-Wales**: D. W. Huws*, R. Thomas (*Welsh Cancer Intelligence and Surveillance Unit*); **European Commission, Joint Research Centre** - **JRC:** *M. Bettio*.

*EUROCARE Steering Committee

[§]**Corresponding authors:** Dr. **Luigino Dal Maso,** Ph.D., Cancer Epidemiology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Via Franco Gallini 2, 33081 Aviano (PN), Italy, Tel: (+39) 0434 659354; Fax: (+39) 0434 659231, E-mail: epidemiology@cro.it

or

Dr. **Silvia Francisci,** National Center for Prevention and Health Promotion, Italian National Institute of Health (ISS), Rome, Italy; (ISS), Viale Regina Elena 299, Rome, Italy, Tel: (+39) 06 4990 4291, Fax: (+39) 06 4990 4285, E-mail: silvia.francisci@iss.it

Word count: 2710

Abstract (word count: 250)

Background: Few studies have estimated the probability of being cured for cancer patients. This study aims to estimate population-based indicators of cancer cure in Europe by type, sex, age, and period.

Methods: EUROCARE-5 dataset (42 population-based cancer registries in 17 countries) included 7.2 million cancer patients diagnosed at ages 15-74 years in 1990-2007 with follow-up to 2008. Mixture-cure models were used to estimate a) life expectancy of fatal cases (LEF), b) cure fraction (CF) as proportion of patients with same death rates as the general population, and c) time to cure (TTC) as time to reach five-year conditional relative survival (CRS)>95%.

Results: LEF ranged from 10 years for chronic lymphocytic leukemia patients to <6 months for those with liver, pancreas, brain, gallbladder, and lung cancers. It was 7.7 years for patients with prostate cancer at age 65-74 years and >5 years for women with breast cancer. The CF was 94% for testis, 87% for thyroid cancer in women (70% in men), 86% for skin melanoma in women (76% in men), 66% for breast, 63% for prostate, and <10% for liver, lung, and pancreatic cancers. TTC was <5 years for testis and thyroid cancer patients diagnosed below age 55 years, and <10 years for stomach, colorectal, corpus uteri, and melanoma patients of all ages. For breast and prostate cancers a small excess (CRS<95%) remained for at least 15 years.

Conclusions: Estimates from this analysis should help reducing unneeded medicalization and costs. They represent an opportunity to improve patients' quality of life.

Key Message

1. Cancer cure indicators are provided for European patients

2. Evidence suggests that several cancer types are curable diseases

3. For patients with some cancers (e.g., thyroid, testis) excess mortality disappears in 2 years

4. Colorectal or endometrial cancer patients: half of them are cured in <10 years

5. Recognizing cancer patients as cured has relevant clinical and social implications

Introduction

More than 50 years have passed since the first definition of ''cure'' for cancer [1]: "...probably a decade or two after treatment, there remains a group of disease-free survivors whose annual death rate from all causes is similar to that of a normal population group of the same sex and age distribution.*"* Several investigations have expanded such definition into the present 'cure fraction' (CF) indicator, i.e., the proportion of diagnosed cancer patients having the same death rates of the general population of the same sex and age [2,3]. The word 'cure' in oncology has been used with several other meanings if applied to individual patients or at population level, often without fitting the cited standard [4]. Moreover, patients with specific neoplasms may also remain relapse-free, or without any measurable sign of disease, for several years after initial treatment, with a small long-term excess risk of relapse or death [5,6].

In populations of western countries, the number of individuals living after a cancer diagnosis (i.e., cancer prevalence) is growing approximately 3% annually [7-10]. They currently represent more than 5% of the overall population in several countries. In addition, a large proportion of people living after a cancer diagnosis (i.e., 24% of cancer patients in Italy [6] and 29% in USA [10]) are alive after 15 years or more since diagnosis. Patients living after a cancer diagnosis include: individuals currently in treatment; those who are relapse-free but remain at excess risk of recurrence or death [6]; and patients who have the same death rates of the general population (i.e., "cured" ones) [11]. Notwithstanding these growing evidences, few studies have categorized prevalent cancer patients according to the probability of being cured [12-19,20].

This study aimed to provide reliable population-based estimates of three indicators of long-term prognosis and cure of cancer patients in Europe, by cancer type, sex, and age. They serve as 'real-world' information on treatment effectiveness to health professionals, on follow-up plans to oncologists [18,21], and on the best resources allocation to policy makers [22]. Moreover, they may be of special interest to the increasing number of people living after a cancer diagnosis [23].

Materials and methods

Data used are from the EUROCARE-5 study, including information of cancer patients diagnosed in 29 European countries and 99 population-based cancer registries (CRs) [24,25]. Study protocol, data quality checks, participating registries, and national registration coverage in the EUROCARE-5 dataset have been extensively described elsewhere [25].

This study included 7.2 million adult (aged 15-74 years) cancer patients, 3.7 million men and 3.5 million women (Appendix 1), collected by 42 CRs, from 17 countries and 19% of the European population, with ≥15 years of registration during 1990-2007 and ≥18 years of follow-up as of 2008. They included, among others, 1.2 million women with breast cancer and 0.7 million men with prostate cancer. Forty-nine percent of men (1.8 million) and 37% of women (1.3 million) received a cancer diagnosis at age 65-74 years. All malignant tumors, but non-melanomatous skin cancer (classified according to ICD-O-3), were eligible and the 32 most frequent cancer types or combinations were presented (Appendix 1).

Relative Survival (RS) between 0 and 18 years of follow-up and corresponding five-year Conditional RS (CRS), conditioned on surviving at a given number (i.e., 1 to 13) of years of follow-up, were calculated using the Ederer II approach [26]. For each cancer type and sex, mixture cure models were applied to RS data, separately by age groups (15–44, 45–54, 55–64, 65–74 years), using a three-year diagnostic period (i.e., 1990-1992,...,2005-2007) as covariate [2,11]. A Weibull distribution was obtained as parametric function for the excess mortality of fatal cases, with independent parameters (shape and scale of Weibull distribution, period) for each cancer type, sex, and age-strata. All models were based on the assumption of linearity in the effect of the diagnostic period. The assumption seems plausible within the examined diagnostic period, since rarely sudden changes in RS trends were observed at a population level. However, this assumption is questionable outside the study period.

The following indicators of long-term survival and cancer cure were estimated using described mixture cure models: a) LEF is defined as the median life expectancy of fatal cases, who will never reach the same death rates of the general population (i.e., the uncured) [2]. It represents a measure of the death risk due to cancer only, as if the other causes of death were not present; b) cure fraction (CF)

is defined as the proportion of cancer patients having the same mortality rates observed in the general population of the same sex and age [2,3]; and c) time to cure (TTC) is defined as the number of years after cancer diagnosis when the excess mortality due to cancer becomes negligible [11,13]. TTC was estimated as the number of years necessary for model-based five-year CRS to reach 95%.

Validation

Cure models converged for every cancer type, sex, and age group. In addition, a visual comparison of RS and CRS data with model-based estimates over an 18-year period of follow-up for all cancer types, age groups, and period of diagnosis (Appendix 2) was examined by the panel of experts involved in this study. The model fitting to the RS data was very good for most cancer types, sex, and ages. TTC was considered uncertain when a difference between data and estimates of more than 10 percentage points of 5-year CRS at 10 years after diagnosis occurred.

A key assumption for the cure models is that the relative survival curves plateau at some point during the observed follow-up interval [27]. When excess mortality (i.e., RS shows a non-negligible decrease until 15-years after diagnosis) estimates of CF should be read only as the proportion of diagnosed cancer patients that will die for causes other than the specific neoplasm and a cure is questionable. LEF was not reliable for thyroid cancer and in some age groups for Hodgkin lymphoma (HL) (≥45 years) and small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) (<65 years), due to the small number of events in the tail of the distribution of fatal cases.

The observed RS was calculated by means of SeerStat software [28], model-based estimation using the SAS NLIN procedure [11].

Results

LEF spanned from 10 years for SLL/CLL patients (8.2 in men, 11.9 in women) at ages 65-74 years to less than six months for those with liver, pancreas, gallbladder, lung, and brain cancer (Table 1). LEF was five years or more for breast cancer patients at all ages, prostate cancer patients aged 65-74 years, leukemia patients aged 55-64 years, and follicular non-Hodgkin lymphoma (NHL) patients aged 15-64 years. For most cancer types LEF decreased with age in both sexes. A marked advantage for

7

women emerged for older NHL patients and younger skin melanoma patients. Only for bladder cancer men showed more favorable LEF than women. Between 1990 and 2000, LEF in patients with breast or prostate cancer and for most lymphoid neoplasms increased by approximately one year (Appendix 3). Conversely, a less than 2-month increase was estimated for all cancers combined and for the most fatal neoplasms (e.g., esophagus, stomach, colon, liver, gallbladder, pancreas, lung, and brain).

The CF was >60% in 2000 for patients with testicular cancers (94%), skin melanoma (76% in men and 86% in women), thyroid cancer (70% in men and 87% in women), HL (67% and 75%), corpus uteri (76%), breast (66%), cervix uteri (64%), and prostate cancers (63%) (Figure 1). Conversely, a CF≤15% in both sexes was estimated for cancers of the pancreas, liver, lung, SLL/CLL, esophagus, myelomas, brain, and gallbladder. The CF increased by a different extent during 1990-2000 for all cancer types (except bladder), in particular, for patients with prostate cancer (from 22% to 63%) and (>10%) for breast, thyroid, colorectal cancers, and follicular NHL (Figure 1). Two third of cancer patients diagnosed at age 15-44 years were expected to be cured (CF=65% in men and 69% in women), while for patients aged 65-74 years CFs were 33% in men and 38% in women (Appendix 4). CF for all cancer types combined increased in Europe from 23% in 1990 to 39% in 2000 among men and from 41% to 51% among women (Figure 1).

The TTC was less than one year for thyroid and testicular cancer patients below the age of 45 years (Table 2). Conversely, a small but not negligible excess risk of death was present even after 10 years since diagnosis for women with breast cancer and for men with prostate cancer. In particular, TTC of approximately 10 years was found in women aged 45-64 years with breast cancer, but it was 15 years or more for those aged below or above 45-64 years. A relevant long-term excess risk of death (TTC≥15 years) remained for patients aged 65-74 years with laryngeal, liver (in men), prostate, bladder, and kidney cancers, and for all hemolymphopoietic neoplasms, but HL below age 45 years having TTC≤3 years in both sexes.

TTC based on a threshold of 90% were also calculated (Appendix 5), and they occurred 3-5 years earlier than those based on threshold of 95% for most cancer types (Table 2).

CF and TTC in the most frequent age groups of individual cancer types showed an inverse correlation except for the most fatal cancer types (Figure 2). Possible clusters of cancer types were:

8

1) those with CF>70% and TTC≤6 years, including HL, skin melanoma, thyroid, testicular, and cervix uteri cancers; 2) those with CFs between 30% and 70% and TTC of <10 years, including corpus uteri, colorectal, connective tissue and breast cancer in women aged 55-64 years; 3) those with CFs between 30% and 70% and TTC of ≥10 years, including prostate, kidney, bladder cancers, and breast cancer in women aged <45 or ≥65 years (Tables 2); 4) those with CFs <30%, including cancers with severe prognoses (e.g., stomach, gallbladder, lung, pancreas) and those with long-term excess risk of death (e.g., most NHL types, myelomas, liver, larynx, ovary).

Discussion

This study furthers the insights on long-term cancer survivors in Europe using cure indicators, in addition to traditional survival measures [12,24]. Our findings strengthen and are consistent with previous national studies, albeit they were derived from different mathematical models, in Europe [11-16,19] or elsewhere [18,20].

According to estimates of CF and TTC, four major clusters of cancer types emerged. The first included testicular or thyroid cancer patients to whom surveillance may be warranted only for the first 1-2 years, since no relevant excess mortality would persist later on [15,18]. Cure was also reached by more than 2/3 of patients with melanoma, HL, and cancer of cervix uteri. The second cluster included patients with colorectal and endometrial cancers for which a cure is reached by approximately half of patients with TTC<10 years [15,18,29]. A third cluster, including patients with breast, bladder, and prostate cancers since, consistently across studies, 50%-to-70% of them were not expected to die because of their neoplasms [12,15,19,30], but a small risk of death persisted for at least 15 years [5,6,15,19]. For most cancer types, prognosis varied considerably according to stage at diagnosis [18] and to expression of tumor markers [6], suggesting that further detailed information is needed for an accurate stratification of follow-up. The fourth major cluster included patients with liver, lung, and pancreatic cancers [14,15,19], with a median 4-6-months survival. Furthermore, these cancers showed small CF changes during the observation period. For patients with these cancer types, as well as most lymphomas and leukemias who have longer survival, an excess mortality, in comparison with the

general population, persisted for a very long period, suggesting that lifelong oncology surveillance is needed [18].

Strengths and limitations

The accuracy of the presented population-based indicators of cancer cure depends on the size of the study population, length and completeness of follow-up, and goodness-of-fit of models used. The large population size allowed estimates of long-term prognosis for some relevant histological subtypes (i.e., diffuse large-B-cell and follicular NHL, and SLL/CLL), rarely examined [31,32]. The follow-up period was adequate to provide reliable LEF, CF, and TTC estimates for most cancer types. This can also be seen as a limitation as long-term follow-up cannot be obtained for recent diagnoses. Inevitably, validated indicators represent observations from the distant past. Projections of cancer survival and cure for more recent cases depend necessarily on questionable assumptions, and are beyond the scope of present report.

Our present results pertain to the pool of populations for which sufficiently long time series of registry data were available. Even though populations from all parts of Europe were included, the overall study population is certainly not fully representative of the overall European population. Also, given the major variation in survival rates between European populations [24], the presented cure measures are likely to vary substantially among European countries as well.

The cure models we used may have potential limitations. For cancers with long-term excess mortality risk, in particular, the available follow-up period may have been insufficient to observe the deaths of all fatal cases, i.e. the plateau in the relative survival curve, a general key assumption of cure models [15,27]. This means that there might have been an identifiability issue of the CF [27]. Moreover, it should be noted that the estimation of TTC is sensible to the choice of the CRS threshold (i.e., the margin of clinical relevance) and to the use of different definitions and statistical models [11,19,33], in particular for prostate or breast cancer. Hence, patients above 75 years of age at diagnosis were excluded from the analyses as cure models are less reliable for older age groups [3]. Other biases may have affected RS and cure indicators, including lead time and length biases [34,35]. Notably, we defined as cured those patients reaching the same mortality rate as that of a comparable group without cancer, with the assumption that cancer patients were exposed to the same risk factors

10

of the general population. However, this is a "conservative" assumption, since cancer patients, even those cured, could have been exposed to risk factors that contributed to causing their cancer and, in turn, were associated with excess risk of death for competing causes [36]. Recent studies [37-39] have suggested that this effect may lead to underestimate CF and overestimate TTC for several cancer types. No confidence interval for LEF, CF, and TTC have been presented, as well sensitivity analyses for different TTC [11] or their variability [19,33], in order to avoid overemphasized estimates of "precision" by means of still largely debated variability measures [33]. The threshold to define TTC (i.e., a low-risk of recurrence/death) is arbitrary and may be based on different assumptions or statistical models [11,13,18,19]. Most importantly, information on prognostic factors (i.e., stage, treatment, recurrence, socioeconomic status), which should have been taken into account as covariates or stratified in our models, is not routinely collected by most European CR. For breast cancer detailed estimates of long-term prognosis by stage and receptor status have been provided in some countries, as well as first attempts to estimate the risk of recurrence, a kind of information not usually reported by CR [6,13,40-42]. These studies have reported that the prognostic effect of stage or cancer subtype lessens with increasing time since diagnosis, suggesting that present indicators may have underestimated cancer cure for subtypes with less advanced stages.

Finally, the presented indicators of cure and survival estimates may have been influenced by overdiagnosis (increasing detection of cancer cases that would not otherwise result in causing symptoms or deaths, without difference in mortality rates as compared to general population) [43]. Overdiagnosis may have had a relevant impact on CF changes emerged for prostate and thyroid cancer in Europe.

Conclusions

The results from the present study confirm the need to reconsider the current paradigm of survivorship as a never-ending experience that "lasts throughout the lifespan" [44]. This definition of survivorship, indeed, fails to recognize the increasing number of patients who has already reached a life expectancy similar to that of the general population.

The awareness that some cancer patients are cured has relevant clinical and social implications, first of all it provides an opportunity to improve quality of life by changing the way 'former' patients view themselves [23]. In a context of considerable resources needed for care of people living after a cancer diagnosis, our findings call for risk-stratified follow-up care for cancer patients [21,45].

AUTHOR'S CONTRIBUTIONS

LDM and SFrancisci (SFi) drafted the study protocol and designed the study with the support of SG and DS. AT, SM, RC, MC, GG, VJ, PM, RDA and the EUROCARE Working Group revised the study protocol, collected data, prepared cleaned data for the study database. CP and AT did the statistical analyses with the support of LDM, SG, and SFi. DS, SM, LB, OB, RC, MC, EC, TD, GG, AG, FG, VJ, PM, LN, GR, MZ, and RDA contributed to validation of statistical models and revised statistical analyses. AD, SFranceschi, DS, and MZ specifically discussed social and clinical implications of study results. All authors contributed to the interpretation of study results, reviewed and approved the final version.

References

1. Easson, EC, Russell MH. Cure of Hodgkin's Disease. Br Med J. 1963;1:1704-1707.

2. De Angelis R, Capocaccia R, Hakulinen T, Soderman B, Verdecchia A. Mixture models for cancer survival analysis: application to population-based data with covariates. Stat Med 1999; 18: 441-454.

3. Andersson TM, Dickman PW, Eloranta S, Lambert PC. Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models. BMC Med Res Methodol. 2011;11:96.

4. Prasad, V. Use of the word "Cure" in the oncology literature. Am J Hosp Palliat Care. 2015;32: 477–483.

5. Janssen-Heijnen ML, van Steenbergen LN, Voogd AC, et al. Small but significant excess mortality compared with the general population for long-term survivors of breast cancer in the Netherlands. Ann Oncol 2014; 25:64-68.

6. Mariotto AB, Zou Z, Zhang F, Howlader N, Kurian AW, Etzioni R. Can We Use Survival Data from Cancer Registries to Learn about Disease Recurrence? The Case of Breast Cancer. Cancer Epidemiol Biomarkers Prev. 2018;27(11):1332-1341.

7. Maddams J, Utley M, Møller H. Projections of cancer prevalence in the United Kingdom, 2010-2040. Br J Cancer 2012; 107:1195-1202.

8. Colonna M, Boussari O, Cowppli-Bony A, et al. Time trends and short term projections of cancer prevalence in France. Cancer Epidemiol. 2018;56:97-105. Erratum in: Cancer Epidemiol. 2018;57:158-159.

9. Guzzinati S, Virdone S, De Angelis R, et al. Characteristics of people living in Italy after a cancer diagnosis in 2010 and projections to 2020. BMC Cancer 2018; 18:169.

10. Miller KD, Nogueira L, Mariotto AB, et al. Cancer treatment and survivorship statistics, 2019. CA Cancer J Clin. 2019; 69:363-385.

11. Dal Maso L, Guzzinati S, Buzzoni C, et al. Long-term survival, prevalence, and cure of cancer: a population-based estimation for 818902 Italian patients and 26 cancer types. Ann Oncol 2014; 25:2251-2260.

12. Francisci S, Capocaccia R, Grande E, et al. The cure of cancer: a European perspective. Eur J Cancer 2009; 45:1067-1079.

13. Janssen-Heijnen MLG, Gondos A, Bray F, et al. Clinical relevance of conditional survival of cancer patients in Europe: Age-specific analyses of 13 cancers. J Clin Oncol 2010; 28: 2520-2528.

14. Cvancarova M, Aagnes B, Fosså SD, Lambert PC, Møller B, Bray F. Proportion cured models applied to 23 cancer sites in Norway. Int J Cancer 2013; 132:1700-1710.

15. Dal Maso L, Panato C, Guzzinati, et al Prognosis of long-term cancer survivors: A population-based estimation. Cancer Med. 2019; 8:4497-4507.

16. Silversmit G, Jegou D, Vaes E, Van Hoof E, Goetghebeur E, Van Eycken L. Cure of cancer for seven cancer sites in the Flemish Region. Int J Cancer 2017; 140:1102-1110.

17. Boussari O, Romain G, Remontet L, et al. A new approach to estimate time-to-cure from cancer registries data. Cancer Epidemiol 2018; 53:72-80.

18. Dood RL, Zhao Y, Armbruster SD, et al. Defining Survivorship Trajectories Across Patients With Solid Tumors: An Evidence-Based Approach. JAMA Oncol 2018; 4:1519-1526.

19. Romain G, Boussari O, Bossard N, et al. Time-to-cure and cure proportion in solid cancers in France. A population based study. Cancer Epidemiol. 2019;60:93-101.

20. Kou K, Dasgupta P, Cramb SM, Yu XQ, Baade PD. Temporal Trends in Population-Level Cure of Cancer: The Australian Context. Cancer Epidemiol Biomarkers Prev. 2020;29:625-635.

21. Tralongo P, Surbone A, Serraino D, Dal Maso L. Major patterns of cancer cure: clinical implications. Eur J Cancer Care, 2019; 28(6):e13139.

22. Laudicella M, Walsh B, Burns E, Smith PC. Cost of care for cancer patients in England: evidence from population-based patient-level data. Br J Cancer 2016; 114:1286-1292.

23. Dumas A, De Vathaire F, Vassal G. Access to loan-related insurance for French cancer survivors. Lancet Oncol 2016; 17:1354-1356.

24. De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014; 15: 23–34.

25. Rossi S, Baili P, Capocaccia R, et al. The EUROCARE-5 study on cancer survival in Europe 1999-2007: database, quality checks and statistical analysis methods. Eur J Cancer 2015;51:2104-2119.

26. Ederer F, Heise H. Instructions to IBM 650 programmers in processing survival computations. Methodological note no. 10. Bethesda, MD: End Results Evaluation Section, National Cancer Institute; 1959.

27. Yu XQ, De Angelis R, Andersson TM, Lambert PC, O'Connell DL, Dickman PW. Estimating the proportion cured of cancer: Some practical advice for users. Cancer Epidemiol 2013; 37: 836-842.

28. Surveillance Research Program, National Cancer Institute. SEER*Stat software. Version 8.3.4; 2017. <http://www.seer.cancer.gov/seerstat/>.

29. Andersson TM, Eriksson H, Hansson J, et al. Estimating the cure proportion of malignant melanoma, an alternative approach to assess long term survival: a population-based study. Cancer Epidemiol. 2014;38:93-99.

30. Stedman MR, Feuer EJ, Mariotto AB. Current estimates of the cure fraction: a feasibility study of statistical cure for breast and colorectal cancer. J Natl Cancer Inst Monogr 2014; 2014:244-254.

31. Howlader N, Mariotto AB, Besson C, et al. Cancer-specific mortality, cure fraction, and noncancer causes of death among diffuse large B-cell lymphoma patients in the immunochemotherapy era. Cancer. 2017;123:3326-3334.

32. Ekberg S, Jerkeman M, Andersson PO, et al. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma. Am J Hematol. 2018; 93:1020-1028.

33. Jakobsen LH, Andersson TM, Biccler JL, et al. On estimating the time to statistical cure. BMC Med Res Methodol. 2020;20:71.

34. Mariotto AB, Noone AM, Howlader N, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr 2014;2014:145-86.

35. Bright CJ, Brentnall AR, Wooldrage K, Myles J, Sasieni P, Duffy SW. Errors in determination of net survival: cause-specific and relative survival settings. Br J Cancer. 2020;122(7):1094-1101.

36. Zaorsky NG, Churilla TM, Egleston BL, et al. Causes of death among cancer patients. Ann Oncol 2017; 28:400-407.

37. Botta L, Gatta G, Trama A, Capocaccia R. Excess risk of dying of other causes of cured cancer patients. Tumori. 2019;105:199-204.

38. Touraine C, Grafféo N, Giorgi R. More accurate cancer-related excess mortality through correcting background mortality for extra variables. Stat Methods Med Res. 2019: doi: 10.1177/0962280218823234.

39. Blakely T, Soeberg M, Carter K, Costilla R, Atkinson J, Sarfati D. Bias in relative survival methods when using incorrect life-tables: lung and bladder cancer by smoking status and ethnicity in New Zealand. Int J Cancer. 2012;131:E974-E982.

40. Van Erning FN, van Steenbergen LN, Lemmens VEPP, et al. Conditional survival for long-term colorectal cancer survivors in the Netherlands: who do best? Eur J Cancer. 2014;50(10):1731-1739.

41. Van Maaren MC, Strobbe LJA, Smidt ML, Moossdorff M, Poortmans PMP, Siesling S. Ten-year conditional recurrence risks and overall and relative survival for breast cancer patients in the Netherlands: Taking account of event-free years. Eur J Cancer. 2018;102:82-94.

42. Van Maaren MC, de Munck L, Strobbe LJA, et al. Ten-year recurrence rates for breast cancer subtypes in the Netherlands: A large population-based study. Int J Cancer. 2019; 144:263-272

43. Vaccarella S, Franceschi S, Bray F, Wild CP, Plummer M, Dal Maso L. Worldwide Thyroid-Cancer Epidemic? The Increasing Impact of Overdiagnosis. N Engl J Med. 2016;375:614-617.

44. Shapiro CL. Cancer survivorship. N Engl J Med. 2018;379:2438-2450.

45. Mayer DK, Alfano CM. Personalized Risk-Stratified Cancer Follow-Up Care: Its Potential for Healthier Survivors, Happier Clinicians, and Lower Costs. J Natl Cancer Inst. 2019;111:442-448.

Legends to figures

Figure 1. Cure fraction (%)[1] by sex, cancer type, and period in Europe

NHL = non-Hodgkin lymphoma
DLBC = diffuse large-B-cell non-Hodgkin lymphoma
SLL/CLL = small lymphocytic lymphoma/chronic lymphocytic leukemia

[1]Calculated as means of corresponding cure fractions estimated for the 4 age groups (Appendix 4) weighted by number of incident cases (Appendix 1).
Patients aged 15-74 years.
*Cancer types with a non negligible long term excess mortality rate, in comparison with general population.
In this case, CF should be interpreted as long term relative survival (i.e., ≥20 years since diagnosis).

Figure 2. Combination of the cure fraction (%) and time to cure[1] by sex for the most frequent age group in Europe

HL = Hodgkin lymphoma; NHL = non-Hodgkin lymphoma; DLBC = diffuse large-B-cell non-Hodgkin lymphoma; SLL/CLL = small lymphocytic lymphoma/chronic lymphocytic leukemia

1Calculated in 2000 for age 65-74 years but oral cavity, skin melanoma, breast (55-64 years), and cervix uteri, testis, thyroid, and Hodgkin lymphoma (15-44 years).
*Cancer types with a non negligible long term excess mortality rate, in comparison with general population. In this case, CF should be interpreted as long term relative survival (i.e., ≥20 years since diagnosis).

Table 1. Life expectancy of fatal cases (years)[1] at diagnosis by cancer type, sex, and age in Europe

Cancer type[2]	Age at diagnosis (years)							
	15-44		45-54		55-64		65-74	
Sex	M	W	M	W	M	W	M	W
All types	**1.2**	**2.7**	**1.0**	**2.3**	**1.0**	**1.6**	**1.0**	**1.0**
Oral cavity and pharynx	1.7	2.4	1.8	2.7	1.8	2.4	1.5	2.2
Esophagus	0.7	0.8	0.7	0.7	0.6	0.7	0.5	0.6
Stomach	0.7	0.7	0.7	0.7	0.6	0.6	0.5	0.5
Colorectal	1.5	1.6	1.6	1.7	1.6	1.5	1.3	1.2
Colon	1.3	1.5	1.3	1.5	1.3	1.3	1.1	1.0
Rectum	1.8	2.0	2.0	2.0	1.9	1.9	1.6	1.6
Liver	0.4	0.6	0.3	0.4	0.3	0.4	0.3	0.3
Gallbladder	0.8	0.7	0.7	0.6	0.6	0.5	0.4	0.3
Pancreas	0.4	0.4	0.3	0.4	0.3	0.4	0.2	0.3
Larynx	2.2	3.0	2.9	4.0	4.1	10.3	4.7	5.2
Lung	0.6	0.7	0.6	0.6	0.5	0.6	0.4	0.4
Skin melanoma	3.1	4.4	2.9	3.6	2.5	3.1	2.4	2.7
Connective tissue	1.6	1.9	1.6	1.7	1.3	1.7	1.1	1.4
Breast		7.1		6.4		5.6		6.4
Vagina		3.2		2.6		2.1		1.7
Cervix uteri		1.9		1.8		2.0		1.7
Corpus uteri		2.9		2.4		2.4		2.1
Ovary		2.0		2.1		1.6		1.1
Prostate	2.2		3.7		4.8		7.7	
Testis	1.3		7.0		2.6		2.0	
Kidney	1.6	1.3	1.9	1.9	1.9	2.0	1.6	2.7
Bladder	2.0	1.0	2.6	1.5	3.5	2.1	3.5	2.2
Brain	2.3	2.7	0.8	0.8	0.5	0.5	0.3	0.3
Hodgkin lymphoma[2]	3.6	3.9	-	-	-	-	-	-
Non-Hodgkin lymphoma	1.3	1.6	7.2	8.9	9.4	15.1	5.7	7.3
Multiple myeloma	4.6	3.7	4.0	4.2	3.5	3.5	2.2	2.4
Leukemias	1.3	1.1	5.0	2.7	5.9	5.8	2.9	3.0
SLL/CLL[2]	-	-	-	-	-	-	8.2	11.9
NHL, diffuse large B-cell	1.0	1.3	1.8	2.2	2.0	2.2	1.6	2.1
NHL, follicular	5.3	4.8	5.1	6.5	5.7	5.4	4.2	4.9

NHL=non-Hodgkin lymphoma
SLL/CLL=small lymphocytic lymphoma/chronic lymphocytic leukemia

[1] Median life expectancy of fatal cases at diagnosis was calculated in years as the median (50th percentile) RS estimated through the best fitting model-based distributions centered at 2000 as the year of diagnosis.
[2] Not estimable for thyroid cancer and some age groups for HL and SLL/CLL.

Table 2. Time to cure measured as Years to reach 5-year Conditional Relative Survival (5-yr CRS) >95%[1] by cancer type[2], sex, and age in Europe

Cancer type	15-44		45-54		55-64		65-74	
	Men	Women	Men	Women	Men	Women	Men	Women
All types	**6**	**8**	**9**	**9**	**10**	**10**	**13**	**12**
Oral cavity and pharynx[2]	8	7	12	13	15	15	17	18
Esophagus[2]	6	6	6	6	7	6	7	6
Stomach	7	7	7	7	7	7	7	8
Colorectal	6	6	7	7	8	7	8	8
Colon	6	6	7	6	7	6	8	7
Rectum	7	7	8	7	9	8	9	9
Liver	10	9	13	10	15	11	20	14
Gallbladder	7	6	7	6	9	7	8	7
Pancreas	8	6	7	6	6	6	6	6
Larynx	9	9	13	18	21	>25	>25	>25
Lung	5	5	7	6	8	8	9	9
Skin melanoma	6	2	6	4	6	4	6	5
Connective tissue	6	7	7	8	7	10	9	12
Breast		16		11		10		15
Vagina		8		9		10		10
Cervix uteri		4		6		10		14
Corpus uteri		5		4		5		7
Ovary		7		9		9		10
Prostate	6		8		9		17	
Testis	<1		1		1		5	
Kidney	7	5	12	9	15	13	17	>25
Bladder	4	3	8	6	14	10	19	16
Brain[2]	18	20	8	10	5	6	5	5
Thyroid	<1	<1	3	<1	8	1	24	8
Hodgkin lymphoma	3	2	14	7	>25	18	>25	>25
Non-Hodgkin lymphoma	7	7	>25	23	>25	>25	>25	>25
Multiple myeloma	21	16	25	24	>25	>25	25	>25
Leukemias	7	7	>25	20	>25	>25	>25	>25
SLL/CLL	>25	>25	>25	>25	>25	>25	>25	>25
NHL, diffuse large B-cell	5	5	11	11	16	15	22	>25
NHL, follicular	10	9	13	14	19	17	19	21

NHL=Non-Hodgkin lymphoma
SLL/CLL =small lymphocytic lymphoma/chronic lymphocytic leukemia

[1] Calculated using model-based 5-yr CRS estimates of time to cure, centered at 2000 as the year of diagnosis.
[2] A poor fitting between observed and model-based CRS emerged for patients with Oral cavity, Esophagus, and Brain cancers.

Figure 1.

Men

Testis	91
Skin melanoma	66 / 76
Thyroid	57 / 70
Hodgkin lymphoma	56 / 67
Prostate*	22 / 63
Connective tissue	42 / 53
NHL, follicular*	28 / 51
Colon	39 / 49
Colonrectal	37 / 49
Bladder*	46 / 48
Rectum	34 / 47
Kidney*	30 / 47
NHL, DLBC*	27 / 40
ALL TYPES	23 / 39
Larynx*	34 / 36
Oral cavity and pharynx*	19 / 27
NHL*	15 / 24
Stomach	14 / 19
Leukemias*	10 / 18
Gallbladder	9 / 14
Brain	10 / 12
Multiple myeloma*	4 / 10
Esophagus	5 / 10
SLL/CLL	3 / 9
Lung*	5 / 8
Liver	2 / 5
Pancreas	3 / 4

■ 1990
■ 2000

Cure fraction (%)

Women

Thyroid	76 / 87
Skin melanoma	79 / 86
Corpus uteri	70 / 76
Hodgkin lymphoma	66 / 75
Breast*	50 / 66
Cervix uteri	60 / 64
Vagina	48 / 52
Rectum	40 / 52
Colon	43 / 52
NHL, follicular*	33 / 52
Colonrectal	41 / 52
Connective tissue	45 / 52
ALL TYPES	41 / 51
Bladder*	50 / 48
Oral cavity and pharynx*	35 / 41
Kidney*	32 / 41
NHL, DLBC*	31 / 40
Ovary	27 / 36
NHL*	20 / 30
Larynx*	22 / 23
Stomach	19 / 23
Leukemias*	13 / 22
Brain	13 / 15
SLL/CLL*	5 / 15
Esophagus	8 / 13
Gallbladder	9 / 13
Multiple myeloma*	5 / 11
Lung*	6 / 10
Liver	4 / 7
Pancreas	3 / 5

■ 1990
■ 2000

Cure fraction (%)

Figure 2.

Men

Women